hapabapa
- Cancer-focused biotech Kura Oncology (NASDAQ:KURA) announced Tuesday the FDA clearance of its Investigational New Drug (IND) application for solid tumor candidate KO-2806.
- The company expects to start the first-in-human study for KO-2806 as a Phase 1 trial in Q3 2023 to test its effectiveness and safety as a monotherapy and combination therapy in adults with advanced solid tumors.
- An inhibitor of farnesyl transferase, KO-2806, is designed to enhance upon the use of a class of drugs called farnesyl transferase inhibitors (FTI).
- "Over the past several years, we have pioneered the development of farnesyl transferase inhibitors as combination agents to prevent or delay emergence of resistance to certain classes of targeted therapy," Chief Executive of Kura (KURA) Troy Wilson remarked.
- In 2021, the company announced FDA's breakthrough therapy designation for FTI tipifarnib as a treatment for a certain form of head and neck squamous cell carcinoma.
- Read: Seeking Alpha contributor Bret Jensen issued a Hold rating on Kura (KURA) after the company's Q3 2022 results.